Evidence map›Paper›PMID 34216957›Full record

ArticleCancer epidemiology2021

Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.

Alem A Belachew, Xifeng Wu, Rashida Callender, Rosalie Waller, Robert Z Orlowski, Celine M Vachon, Nicola J Camp, Elad Ziv, Michelle A T Hildebrandt

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Alem A BelachewDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.
Rashida CallenderDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.
Rosalie WallerDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, 84108, United States.
Robert Z OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.
Celine M VachonDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55902, United States.
Nicola J CampDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, 84108, United States.
Elad ZivDepartment of Medicine, Division of General Internal Medicine, Institute for Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, 94143, United States.
Michelle A T HildebrandtDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States. Electronic address: mhildebr@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Utah · USMayo Clinic in Florida · USUniversity of California, San Francisco · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA142509
6 · The paper itself

Abstract

backgroundAberrant Wnt/beta-catenin pathway activation is implicated in Multiple Myeloma (MM) development, but little is known if genetic variants within this pathway contribute to MM susceptibility.

methodsWe performed a discovery candidate pathway analysis in 269 non-Hispanic white MM cases and 272 controls focusing on 171 variants selected from 26 core genes within the Wnt/beta-catenin pathway. Significant candidate variants (P < 0.05) were selected for validation in internal and external non-Hispanic white populations totaling 818 cases and 1209 controls. We also examined significant variants in non-Hispanic black and Hispanic case/control study populations to identify potential differences by race/ethnicity. Possible biological functions of candidate variants were predicted in silico.

resultsSeven variants were significantly associated with MM risk in non-Hispanic whites in the discovery population, of which LRP6:rs7966410 (OR: 0.57; 95 % CI: 0.38-0.88; P = 9.90 × 10

conclusionWe identified several variants within the Wnt/beta-catenin pathway associated with MM susceptibility. Findings of this study highlight the potential genetic role of Wnt/beta-catenin signaling in MM etiology among a diverse patient population.

Indexed as

beta CateninMultiple MyelomaWnt Signaling PathwayAgedBlack or African AmericanCase-Control StudiesFemaleGenetic Predisposition to DiseaseHispanic or LatinoHumansMaleMiddle AgedWhite Peoplebeta CateninDisparitiesGenetic variationMyelomaSusceptibilityWnt/beta-catenin

Identifiers

PMID34216957
PMCPMC8351401
OpenAlexW3179976030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.